Gothenberg, Sweden-based biotech Isofol Medical AB expects to start a pivotal Phase III study at the end of 2017 with its single asset, Modufolin, potentially a more effective product to combine with 5-fluorouracil (5-FU) than conventional Leucovorin (folinic acid).
The company is currently working on raising new funds for the study that could include an initial public offering. Over...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?